Dermapharm Holding SEFRA:DMP 87 Gross Margin % is 67.92% as of Mar. 2026, which is 12% above its 10-year median of 60.87. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 938 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 79.64% on this metric.
FRA:DMP's Gross Margin % is ranked better than 79.64% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs FRA:DMP: 67.74
Dermapharm Holding SE had a gross margin of 67.92% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Dermapharm Holding SE was 1.90% per year.
Dermapharm Holding SE (FRA:DMP) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Dermapharm Holding SE had a gross margin of 67.92% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Dermapharm Holding SE Gross Margin % Related Terms
Dermapharm Holding SE Gross Margin % Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DMP vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Dermapharm Holding SE (FRA:DMP) has a Gross Margin % of 67.92% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Dermapharm Holding SE and its competitors. This is 12% above median its historical median of 60.87. Over the past decade, Dermapharm Holding SE's Gross Margin % has ranged from 45.23 to 67.74. According to the industry distribution chart, Dermapharm Holding SE ranks #191 out of 938 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Dermapharm Holding SE's Gross Margin % too high?
Dermapharm Holding SE's current Gross Margin % of 67.92% is 12% above median its 10-year median of 60.87. Over the past 10 years, this metric has ranged from a low of 45.23 to a high of 67.74. The Drug Manufacturers industry median Gross Margin % is 48.44. Dermapharm Holding SE's value of 67.92% is 40.2% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #191 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #191 out of 938 companies for Gross Margin %. This places Dermapharm Holding SE in the top 20% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.44. Dermapharm Holding SE's value of 67.92% is 40.2% above this benchmark. Historically, Dermapharm Holding SE's own Gross Margin % has ranged from 45.23 to 67.74 over the past decade. While the company's 10-year median is 60.87 vs. the industry median of 48.44, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current Gross Margin % of 67.92% is 40.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current Gross Margin % is 67.92%, which is 12% above median its own 10-year median of 60.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current Gross Margin % is 67.92%, which is 12% above median its 10-year median of 60.87 and 40.2% above the Drug Manufacturers industry median of 48.44. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current Gross Margin % is 67.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11.
GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.
Key valuation signals for FRA:DMP:
Gross Margin %: 67.92% (12% above median its 10-year median of 60.87)
GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
Industry Position: 40.2% above the Drug Manufacturers median (#191 of 938)
No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score
Get the complete analysis for FRA:DMP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMP has been successfully added to your 
